Vaxcyte Welcomes Dr. Olivier Brandicourt, Former Sanofi CEO, To Its Board of Directors

Vaxcyte, Inc., a biotechnology company dedicated to developing high-precision vaccines to address serious bacterial infections, has announced the appointment of Dr. Olivier Brandicourt to its Board of Directors. Dr. Brandicourt brings extensive experience in the global biopharmaceutical industry, having previously served as Chief Executive Officer of Sanofi S.A. 

Throughout his career, he has held various senior leadership roles across major pharmaceutical companies and brings a deep understanding of vaccine development, global healthcare markets, and strategic business growth. His addition to the Board is expected to support Vaxcyte's continued progress in advancing its innovative vaccine pipeline.

Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte, said in a statement, “We are thrilled to welcome Olivier to Vaxcyte’s Board of Directors. He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market. During his time as the CEO of Sanofi, he further bolstered the company’s standing as one of the world’s leading commercial vaccine companies. His strategic insight and operational leadership will be instrumental as we advance toward the potential global commercialization of our pneumococcal conjugate vaccine (PCV) candidates. Separately, I would like to extend our sincere thanks to Dr. Peter Hirth, who has served on the Board since 2016 and will conclude his tenure in June. We are deeply grateful for his years of dedicated service and myriad contributions to Vaxcyte during a defining period in our growth.”

Dr. Brandicourt stated, “Vaxcyte’s carrier-sparing platform represents a highly differentiated and scientifically compelling approach, with the potential to address some of the most pressing unmet needs in the prevention of bacterial diseases. I’m honored to join the Board at such a pivotal time and look forward to working with the team as the Company continues to advance its PCV candidates toward potential commercialization. By broadening protection against invasive pneumococcal disease, Vaxcyte is not only aiming to set a new standard of care—it is also contributing to the global effort to combat antimicrobial resistance, a pervasive public health threat driven by the overuse of antibiotics.”